Mga Batayang Estadistika
| LEI | 529900NQNTTXYE874283 |
| CIK | 1610820 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BriaCell Therapeutics Corp. - Equity Warrant
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 26, 2025 |
BriaCell Announces Proposed Effective Date of Share Consolidation Exhibit 99.1 BriaCell Announces Proposed Effective Date of Share Consolidation PHILADELPHIA and VANCOUVER, British Columbia, Aug. 21, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that the Company’s board of |
|
| August 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 21, 2025 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British ColumbiaA1 47-1099599 (State or other jurisdiction of incorporation or organ |
|
| August 1, 2025 |
As filed with the Securities and Exchange Commission on July 31, 2025 As filed with the Securities and Exchange Commission on July 31, 2025 Registration No. |
|
| August 1, 2025 |
Exhibit 107 Calculation of Filing Fee Table FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Form Type) BRIACELL THERAPEUTICS CORP. |
|
| July 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 15, 2025 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British ColumbiaA1 47-1099599 (State or other jurisdiction of incorporation or organiz |
|
| July 16, 2025 |
COMMON SHARES PURCHASE WARRANT BRIACELL THERAPEUTICS CORP. Exhibit 4.1 COMMON SHARES PURCHASE WARRANT BRIACELL THERAPEUTICS CORP. Warrant Shares: Initial Exercise Date: July 16, 2025 THIS WARRANT TO PURCHASE COMMON SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after July 16, 2025 (the |
|
| July 16, 2025 |
BriaCell Therapeutics Announces Pricing of $15 million Public Offering Exhibit 99.1 BriaCell Therapeutics Announces Pricing of $15 million Public Offering PHILADELPHIA and VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of a best |
|
| July 16, 2025 |
BriaCell Therapeutics Announces Closing of $15 million Public Offering Exhibit 99.2 BriaCell Therapeutics Announces Closing of $15 million Public Offering Philadelphia & Vancouver, British Columbia – July 16, 2025 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its best-efforts public |
|
| July 16, 2025 |
Exhibit 1.1 PLACEMENT AGENCY AGREEMENT between BRIACELL THERAPEUTICS CORP. and THINKEQUITY LLC BRIACELL THERAPEUTICS CORP. PLACEMENT AGENCY AGREEMENT New York, New York July 15, 2025 ThinkEquity LLC 17 State Street, 41st Fl New York, NY 10004 Ladies and Gentlemen: This Placement Agency Agreement (the “Agreement”) sets forth the terms upon which ThinkEquity LLC (“ThinkEquity” or the “Placement Agen |
|
| July 16, 2025 |
ThinkEquity The date of this prospectus is July 15, 2025. TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(4) Registration No. 333-288562 PROSPECTUS 10,775,000 Common Units, Each Common Unit Consisting of One Common Share and One Warrant to Purchase One Common Share 1,225,000 Pre-Funded Units, Each Consisting of One Pre-Funded Warrant and One Warrant to Purchase One Common Share 10,775,000 Common Shares included in the Common Units 1,225,000 Pre-Funded Warrants included in |
|
| July 16, 2025 |
PRE-FUNDED COMMON SHARES PURCHASE WARRANT BRIACELL THERAPEUTICS CORP. Exhibit 4.2 PRE-FUNDED COMMON SHARES PURCHASE WARRANT BRIACELL THERAPEUTICS CORP. Warrant Shares: Issue Date: July 16, 2025 THIS PRE-FUNDED COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue D |
|
| July 15, 2025 |
BriaCell Therapeutics Corp. Suite 300 - 235 15th Street West Vancouver, BC V7T 2X1 BriaCell Therapeutics Corp. Suite 300 - 235 15th Street West Vancouver, BC V7T 2X1 July 15, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Attention: Alan Campbell Re: BriaCell Therapeutics Corp. (the “Company”) Registration Statement on Form S-1 (the “Registration Statement”) File No. 333-288562 Ladies and Gentlemen: T |
|
| July 15, 2025 |
ThinkEquity LLC 17 State Street, 41st Floor New York, NY 10004 ThinkEquity LLC 17 State Street, 41st Floor New York, NY 10004 July 15, 2025 VIA EDGAR U. |
|
| July 14, 2025 |
ThinkEquity LLC 17 State Street, 41st Floor New York, NY 10004 ThinkEquity LLC 17 State Street, 41st Floor New York, NY 10004 July 14, 2025 VIA EDGAR U. |
|
| July 14, 2025 |
BriaCell Therapeutics Corp. Suite 300 - 235 15th Street West Vancouver, BC V7T 2X1 BriaCell Therapeutics Corp. Suite 300 - 235 15th Street West Vancouver, BC V7T 2X1 July 14, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Attention: Alan Campbell Re: BriaCell Therapeutics Corp. (the “Company”) Registration Statement on Form S-1 (the “Registration Statement”) File No. 333-288562 Ladies and Gentlemen: T |
|
| July 11, 2025 |
BriaCell Therapeutics Corp. Suite 300 - 235 15th Street West Vancouver, BC V7T 2X1 BriaCell Therapeutics Corp. Suite 300 - 235 15th Street West Vancouver, BC V7T 2X1 July 11, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Attention: Alan Campbell Re: BriaCell Therapeutics Corp. (the “Company”) Registration Statement on Form S-1 (the “Registration Statement”) File No. 333-288562 Ladies and Gentlemen: T |
|
| July 11, 2025 |
ThinkEquity LLC 17 State Street, 41st Floor New York, NY 10004 ThinkEquity LLC 17 State Street, 41st Floor New York, NY 10004 July 11, 2025 VIA EDGAR U. |
|
| July 11, 2025 | ||
| July 10, 2025 |
Exhibit 4.22 FORM OF COMMON SHARES PURCHASE WARRANT BRIACELL THERAPEUTICS CORP. Warrant Shares: Initial Exercise Date: ♦, 2025 THIS WARRANT TO PURCHASE COMMON SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after ♦, 2025 (the “I |
|
| July 10, 2025 |
Form of Placement Agency Agreement by and between BriaCell Therapeutics Corp. and ThinkEquity LLC Exhibit 1.1 PLACEMENT AGENCY AGREEMENT between BRIACELL THERAPEUTICS CORP. and THINKEQUITY LLC BRIACELL THERAPEUTICS CORP. PLACEMENT AGENCY AGREEMENT New York, New York July [*], 2025 ThinkEquity LLC 17 State Street, 41st Fl New York, NY 10004 Ladies and Gentlemen: This Placement Agency Agreement (the “Agreement”) sets forth the terms upon which ThinkEquity LLC (“ThinkEquity” or the “Placement Age |
|
| July 10, 2025 |
As filed with the U.S. Securities and Exchange Commission on July 10, 2025. As filed with the U.S. Securities and Exchange Commission on July 10, 2025. Registration No. 333-288562 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 2834 47-1099599 (State or other jurisdic |
|
| July 10, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BRIACELL THERAPEUTICS CORP. |
|
| July 9, 2025 |
As filed with the U.S. Securities and Exchange Commission on July 9, 2025. As filed with the U.S. Securities and Exchange Commission on July 9, 2025. Registration No. 333-288562 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 2834 47-1099599 (State or other jurisdict |
|
| July 8, 2025 |
ThinkEquity LLC 17 State Street, 41st Floor New York, NY 10004 ThinkEquity LLC 17 State Street, 41st Floor New York, NY 10004 July 8, 2025 VIA EDGAR U. |
|
| July 8, 2025 |
Form of Placement Agency Agreement by and between BriaCell Therapeutics Corp. and ThinkEquity LLC Exhibit 1.1 PLACEMENT AGENCY AGREEMENT between BRIACELL THERAPEUTICS CORP. and THINKEQUITY LLC BRIACELL THERAPEUTICS CORP. PLACEMENT AGENCY AGREEMENT New York, New York July [*], 2025 ThinkEquity LLC 17 State Street, 41st Fl New York, NY 10004 Ladies and Gentlemen: This Placement Agency Agreement (the “Agreement”) sets forth the terms upon which ThinkEquity LLC (“ThinkEquity” or the “Placement Age |
|
| July 8, 2025 |
Exhibit 4.21 FORM OF PRE-FUNDED COMMON SHARES PURCHASE WARRANT BRIACELL THERAPEUTICS CORP. Warrant Shares: Issue Date: , 2025 THIS PRE-FUNDED COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue |
|
| July 8, 2025 |
Form of Placement Agent’s Warrant Exhibit 4.22 Form of Placement Agent’s Warrant Agreement WARRANT TO PURCHASE COMMON SHARES BRIACELL THERAPEUTICS CORP. Warrant Shares: Initial Exercise Date: , 2025 THIS WARRANT TO PURCHASE COMMON SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, a |
|
| July 8, 2025 |
Exhibit 4.20 FORM OF FIRST AMENDMENT TO WARRANT AGENT AGREEMENT BriaCell Therapeutics Corp., a company incorporated under the laws of British Columbia (the “Company”), and Computershare Inc., a Delaware corporation, and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company, collectively as Warrant Agent (the “Warrant Agent”) agree to this first amendment (this “Amen |
|
| July 8, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BRIACELL THERAPEUTICS CORP. |
|
| July 8, 2025 |
July 8, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Attention: Alan Campbell Re: BriaCell Therapeutics Corp. Registration Statement on Form S-1 File No. 333-288562 Filed July 8, 2025 Ladies and Gentlemen: BriaCell Therapeutics Corp. (the “Company”) hereby requests acceleration of the effective date of the above-refer |
|
| July 8, 2025 |
As filed with the U.S. Securities and Exchange Commission on July 8, 2025. As filed with the U.S. Securities and Exchange Commission on July 8, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 2834 47-1099599 (State or other jurisdiction of incorporation or o |
|
| July 8, 2025 | ||
| June 18, 2025 |
As confidentially submitted to the U.S. Securities and Exchange Commission on June 18, 2025. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURIT |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 16, 2025 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British ColumbiaA1 47-1099599 (State or other jurisdiction of incorporation or organiz |
|
| June 18, 2025 |
Exhibit 99.2 BRIAPRO THERAPEUTICS CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS For the three and nine months ended April 30, 2025 (Expressed in U.S. Dollars) The following Management’s Discussion and Analysis (“MD&A”) for BRIAPRO THERAPEUTICS CORP. (“BriaPro” or the “Company”) is prepared as of June 16, 2025 and relates to the unaudited condensed interim financial condition and results of operations |
|
| June 18, 2025 |
June 18, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Re: BriaCell Therapeutics Corp. (the “Company”) Draft Registration Statement on Form S-1 Filed June 18, 2025 Ladies and Gentlemen: The Company affirms that the above-referenced Registration Statement on Form S-1 (the “Registration Statement”) confidentially submitt |
|
| June 18, 2025 |
Exhibit 99.1 BRIAPRO THERAPEUTIC CORP. CONDESED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTH PERIOD ENDED APRIL 30, 2025 (Unaudited) (Expressed in United States Dollars) NOTICE TO SHAREHOLDERS The accompanying Unaudited Condensed Interim Consolidated Financial Statements of BriaPro Therapeutics Corp.. for the three and nine month periods ended April 30, 2025 and 2024 have |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40101 BRIACELL THERAPE |
|
| April 28, 2025 |
Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-286670 and 333-286735 PROSPECTUS 2,005,967 Common Units, Each Consisting of a Common Share and a Warrant to Purchase One Common Share 660,700 Pre-funded Units, Each Consisting of a Pre-funded Warrant to Purchase One Common Share and a Warrant to Purchase One Common Share 2,005,967 Common Shares included in the Common Units 2,666,667 Warrants i |
|
| April 28, 2025 |
Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-286670 and 333-286735 PROSPECTUS 2,005,967 Common Units, Each Consisting of a Common Share and a Warrant to Purchase One Common Share 660,700 Pre-funded Units, Each Consisting of a Pre-funded Warrant to Purchase One Common Share and a Warrant to Purchase One Common Share 2,005,967 Common Shares included in the Common Units 2,666,667 Warrants i |
|
| April 28, 2025 |
Exhibit 4.2 Form of Pre-Funded Warrant Certificate PRE-FUNDED COMMON SHARES PURCHASE WARRANT BRIACELL THERAPEUTICS CORP. Warrant Shares: Issue Date: April 28, 2025 THIS PRE-FUNDED COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set fo |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 24, 2025 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) A1 British Columbia 47-1099599 (State or other jurisdiction of incorporation or organ |
|
| April 28, 2025 |
Exhibit 4.1 FORM OF WARRANT TO PURCHASE COMMON SHARES BRIACELL THERAPEUTICS CORP. Warrant Shares: Initial Exercise Date: April 28, 2025 THIS WARRANT TO PURCHASE COMMON SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after April |
|
| April 28, 2025 |
Exhibit 10.1 WARRANT AGENT AGREEMENT WARRANT AGENT AGREEMENT (this “Warrant Agreement”) dated as of April 25, 2025 (the “Issuance Date”) between BriaCell Therapeutics Corp., a company incorporated under the laws of British Columbia (the “Company”), and Computershare Inc., a Delaware corporation (“Computershare”), and its affiliate, Computershare Trust Company, N.A., a federally chartered trust com |
|
| April 28, 2025 |
BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering Exhibit 99.1 BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering PHILADELPHIA and VANCOUVER, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) - BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of an underwr |
|
| April 28, 2025 |
Exhibit 4.3 Form of Representative’s Warrant Agreement WARRANT TO PURCHASE COMMON SHARES BRIACELL THERAPEUTICS CORP. Warrant Shares: Initial Exercise Date: April 28, 2025 THIS WARRANT TO PURCHASE COMMON SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set fo |
|
| April 28, 2025 |
Exhibit 1.1 UNDERWRITING AGREEMENT between BRIACELL THERAPEUTICS CORP. and THINKEQUITY LLC as Representative of the Several Underwriters BRIACELL THERAPEUTICS CORP. UNDERWRITING AGREEMENT New York, New York April 24, 2025 ThinkEquity LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 41st Fl New York, NY 10004 Ladies and Gentlemen: The undersigne |
|
| April 28, 2025 |
BriaCell Therapeutics Announces Closing of $13.8 million Public Offering Exhibit 99.2 BriaCell Therapeutics Announces Closing of $13.8 million Public Offering Philadelphia & Vancouver, British Columbia – April 28, 2025 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced und |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 BriaCell Therapeutics Corp. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identi |
|
| April 24, 2025 |
Form of Warrant Agent Agreement Exhibit 10.1 WARRANT AGENT AGREEMENT WARRANT AGENT AGREEMENT (this “Warrant Agreement”) dated as of , 2025 (the “Issuance Date”) between BriaCell Therapeutics Corp., a company incorporated under the laws of British Columbia (the “Company”), and Computershare Inc., a Delaware corporation (“Computershare”), and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company, co |
|
| April 24, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BRIACELL THERAPEUTICS CORP. |
|
| April 24, 2025 |
As filed with the Securities and Exchange Commission on April 24, 2025 As filed with the Securities and Exchange Commission on April 24, 2025 Registration No. |
|
| April 24, 2025 |
Exhibit 4.1 FORM OF WARRANT TO PURCHASE COMMON SHARES BRIACELL THERAPEUTICS CORP. Warrant Shares: Initial Exercise Date: , 2025 THIS WARRANT TO PURCHASE COMMON SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after , 2025 (the “I |
|
| April 23, 2025 |
As filed with the Securities and Exchange Commission on April 23, 2025 As filed with the Securities and Exchange Commission on April 23, 2025 Registration No. |
|
| April 23, 2025 |
Exhibit 10.33 WARRANT AGENT AGREEMENT WARRANT AGENT AGREEMENT (this “Warrant Agreement”) dated as of , 2025 (the “Issuance Date”) between BriaCell Therapeutics Corp., a company incorporated under the laws of British Columbia (the “Company”), and Computershare Inc., a Delaware corporation (“Computershare”), and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company, c |
|
| April 23, 2025 |
Exhibit 4.15 FORM OF WARRANT TO PURCHASE COMMON SHARES BRIACELL THERAPEUTICS CORP. Warrant Shares: Initial Exercise Date: , 2025 THIS WARRANT TO PURCHASE COMMON SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after , 2025 (the “ |
|
| April 22, 2025 |
Exhibit 4.14 Form of Pre-Funded Warrant PRE-FUNDED COMMON SHARES PURCHASE WARRANT BRIACELL THERAPEUTICS CORP. Warrant Shares: Issue Date: , 2025 THIS PRE-FUNDED COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on |
|
| April 22, 2025 | ||
| April 22, 2025 |
Exhibit 4.1 Form of Representative’s Warrant Agreement WARRANT TO PURCHASE COMMON SHARES BRIACELL THERAPEUTICS CORP. Warrant Shares: Initial Exercise Date: , 2025 THIS WARRANT TO PURCHASE COMMON SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at |
|
| April 22, 2025 |
Form of Warrant Agent Agreement Exhibit 10.33 WARRANT AGENT AGREEMENT WARRANT AGENT AGREEMENT (this “Warrant Agreement”) dated as of , 2025 (the “Issuance Date”) between BriaCell Therapeutics Corp., a company incorporated under the laws of British Columbia (the “Company”), and Computershare Inc., a Delaware corporation (“Computershare”), and its wholly-owned subsidiary, Computershare Trust Company, N.A., a federally chartered tr |
|
| April 22, 2025 |
ThinkEquity LLC 17 State Street, 41st Floor New York, NY 10004 ThinkEquity LLC 17 State Street, 41st Floor New York, NY 10004 April 22, 2025 VIA EDGAR U. |
|
| April 22, 2025 |
Form of Underwriting Agreement by and between BriaCell Therapeutics Corp. and ThinkEquity LLC Exhibit 1.1 UNDERWRITING AGREEMENT between BRIACELL THERAPEUTICS CORP. and THINKEQUITY LLC as Representative of the Several Underwriters BRIACELL THERAPEUTICS CORP. UNDERWRITING AGREEMENT New York, New York April [●], 2025 ThinkEquity LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 41st Fl New York, NY 10004 Ladies and Gentlemen: The undersign |
|
| April 22, 2025 |
As filed with the Securities and Exchange Commission on April 22, 2025 As filed with the Securities and Exchange Commission on April 22, 2025 Registration No. |
|
| April 22, 2025 |
April 22, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Attention: Tyler Howes and Jason Drory Re: BriaCell Therapeutics Corp. Registration Statement on Form S-1 CIK No. 0001610820 Filed April 22, 2025 Ladies and Gentlemen: BriaCell Therapeutics Corp. (the “Company”) hereby requests acceleration of the effective date o |
|
| April 22, 2025 |
Form of Representative’s Warrant Exhibit 4.16 Form of Representative’s Warrant Agreement WARRANT TO PURCHASE COMMON SHARES BRIACELL THERAPEUTICS CORP. Warrant Shares: Initial Exercise Date: , 2025 THIS WARRANT TO PURCHASE COMMON SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at |
|
| April 22, 2025 |
April 22, 2025 BY EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Tyler Howes Jason Drory Re: BriaCell Therapeutics Corp. Draft Registration Statement on Form S-1 Submitted: March 12, 2025 CIK No. 0001610820 Ladies and Gentlemen: This letter is submitted by BriaCell Therapeutics Corp. (the “Compan |
|
| April 22, 2025 |
Exhibit 4.15 FORM OF WARRANT TO PURCHASE COMMON SHARES BRIACELL THERAPEUTICS CORP. Warrant Shares: Initial Exercise Date: , 2025 THIS WARRANT TO PURCHASE COMMON SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after , 2025 (the “ |
|
| April 22, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BRIACELL THERAPEUTICS CORP. |
|
| March 12, 2025 |
Exhibit 99.1 BRIAPRO THERAPEUTIC CORP. CONDESED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTH PERIOD ENDED JANUARY 31, 2025 (Unaudited) (Expressed in United States Dollars) NOTICE TO SHAREHOLDERS The accompanying Unaudited Condensed Interim Consolidated Financial Statements of BriaPro Therapeutics Corp.. for the three and six month periods ended January 31, 2025 and 2024 ha |
|
| March 12, 2025 |
Exhibit 99.2 BRIAPRO THERAPEUTICS CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS For the three and six months ended January 31, 2025 (Expressed in U.S. Dollars) The following Management’s Discussion and Analysis (“MD&A”) for BRIAPRO THERAPEUTICS CORP. (“BriaPro” or the “Company”) is prepared as of March 12, 2025 and relates to the unaudited condensed interim financial condition and results of operatio |
|
| March 12, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 12, 2025 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organiza |
|
| March 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40101 BRIACELL THERA |
|
| March 12, 2025 |
As confidentially submitted to the U.S. Securities and Exchange Commission on March 12, 2025. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURI |
|
| March 12, 2025 |
March 12, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Re: BriaCell Therapeutics Corp. (the “Company”) Draft Registration Statement on Form S-1 File No. 333- Filed March 12, 2025 Ladies and Gentlemen: The Company affirms that the above-referenced Registration Statement on Form S-1 (the “Registration Statement”) confid |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 12, 2025 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organ |
|
| February 10, 2025 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-1 2 g084690ex-1.htm EXHIBIT 1 EXHIBIT 1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing ag |
|
| February 6, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 5, 2025 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organi |
|
| February 5, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFF |
|
| February 5, 2025 |
BriaCell Therapeutics Announces Pricing of Public Offering Exhibit 99.2 BriaCell Therapeutics Announces Pricing of Public Offering PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts public off |
|
| February 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 3, 2025 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organi |
|
| February 5, 2025 |
Exhibit 10-1 PLACEMENT AGENCY AGREEMENT between BRIACELL THERAPEUTICS CORP. and THINKEQUITY LLC BRIACELL THERAPEUTICS CORP. PLACEMENT AGENCY AGREEMENT New York, New York February 3, 2025 ThinkEquity LLC 17 State Street, 41st Fl New York, NY 10004 Ladies and Gentlemen: This Placement Agency Agreement (the “Agreement”) sets forth the terms upon which ThinkEquity LLC (“ThinkEquity” or the “Placement |
|
| February 5, 2025 |
BriaCell Therapeutics Announces Closing of Public Offering Exhibit 99.3 BriaCell Therapeutics Announces Closing of Public Offering Philadelphia & Vancouver, British Columbia – February 5, 2025 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts pu |
|
| February 5, 2025 |
BriaCell Therapeutics Announces Proposed Public Offering of Common Shares Exhibit 99.1 BriaCell Therapeutics Announces Proposed Public Offering of Common Shares PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced that it intends to offer |
|
| February 4, 2025 |
ThinkEquity The date of this prospectus supplement is February 3, 2025 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-276650 PROSPECTUS SUPPLEMENT (To Prospectus dated January 31, 2024) 762,500 Common Shares BriaCell Therapeutics Corp. BriaCell Therapeutics Corp. (the “Company” or “BriaCell”) is offering 762,500 common shares, no par value, of the Company (the “common shares”), at an offering price of $4.00 per share, pursuant to this prospectus supplement and |
|
| February 3, 2025 |
ThinkEquity The date of this prospectus supplement is February , 2025 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-276650 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securit |
|
| January 28, 2025 |
BriaCell Announces Completion of 15:1 Share Consolidation Exhibit 99.1 BriaCell Announces Completion of 15:1 Share Consolidation PHILADELPHIA and VANCOUVER, British Columbia, January 27, 2025 (GLOBE NEWSWIRE) - BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announces that on January 24, 2025 (the “Effective Date |
|
| January 28, 2025 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 24, 2025 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organi |
|
| January 3, 2025 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 3, 2025 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organiz |
|
| January 3, 2025 |
BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025 Exhibit 99.1 BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025 PHILADELPHIA and VANCOUVER, British Columbia, January 3, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that |
|
| January 3, 2025 |
BriaCell Announces Proposed Effective Date of Share Consolidation Exhibit 99.1 BriaCell Announces Proposed Effective Date of Share Consolidation PHILADELPHIA and VANCOUVER, British Columbia, January 3, 2025 (GLOBE NEWSWIRE) - BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that the Company’s board of dire |
|
| January 3, 2025 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 3, 2025 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organiz |
|
| January 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stateme |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 12, 2024 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organ |
|
| December 16, 2024 |
Exhibit 99.2 BRIAPRO THERAPEUTICS CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS For the three months ended October 31, 2024 (Expressed in U.S. Dollars) The following Management’s Discussion and Analysis (“MD&A”) for BRIAPRO THERAPEUTICS CORP. (“BriaPro” or the “Company”) is prepared as of December 12, 2024 and relates to the unaudited condensed interim financial condition and results of operations of |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40101 BRIACELL THERA |
|
| December 16, 2024 |
Exhibit 99.1 BRIAPRO THERAPEUTIC CORP. CONDESED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTH PERIOD ENDED OCTOBER 31, 2024 (Unaudited) (Expressed in United States Dollars) F-1 BriaPro Therapeutics Corp. Unaudited Condensed Interim Consolidated Statements of Financial Position As at October 31, 2024 (Expressed in US Dollars) October 31, 2024 July 31, 2024 (Audited) ASSETS CURRENT A |
|
| December 13, 2024 |
BriaCell Therapeutics Announces Proposed Public Offering Exhibit 99.1 BriaCell Therapeutics Announces Proposed Public Offering PHILADELPHIA and VANCOUVER, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced that it intends to offer to sell common sh |
|
| December 13, 2024 |
BriaCell Therapeutics Announces Closing of $5.5 Million Public Offering Exhibit 99.3 BriaCell Therapeutics Announces Closing of $5.5 Million Public Offering Philadelphia & Vancouver, British Columbia – December 13, 2024 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced u |
|
| December 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 11, 2024 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organ |
|
| December 13, 2024 |
BriaCell Therapeutics Announces Pricing of $5.5 Million Public Offering Exhibit 99.2 BriaCell Therapeutics Announces Pricing of $5.5 Million Public Offering PHILADELPHIA and Vancouver, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of an underwrit |
|
| December 13, 2024 |
Exhibit 4.1 COMMON SHARES PURCHASE WARRANT BRIACELL THERAPEUTICS CORP. Warrant Shares: Initial Exercise Date: December 13, 2024 THIS WARRANT TO PURCHASE COMMON SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after December 13, 2 |
|
| December 13, 2024 |
Exhibit 1.1 UNDERWRITING AGREEMENT between BRIACELL THERAPEUTICS CORP. and THINKEQUITY LLC as Representative of the Several Underwriters BRIACELL THERAPEUTICS CORP. UNDERWRITING AGREEMENT New York, New York December 11, 2024 ThinkEquity LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 41st Fl New York, NY 10004 Ladies and Gentlemen: The undersi |
|
| December 13, 2024 |
Exhibit 4.2 Representative’s Warrant Agreement WARRANT TO PURCHASE COMMON SHARES BRIACELL THERAPEUTICS CORP. Warrant Shares: Initial Exercise Date: December 13, 2024 THIS WARRANT TO PURCHASE COMMON SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, |
|
| December 12, 2024 |
BCTX / BriaCell Therapeutics Corp. / L5 Capital Inc. Activist Investment SC 13D/A 1 formsc13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 4)* BriaCell Therapeutics Corp. (Name of Issuer) COMMON SHARES, NO PAR VALUE (Title of Class of Securiti |
|
| December 12, 2024 |
ThinkEquity The date of this prospectus supplement is December 11, 2024 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-276650 PROSPECTUS SUPPLEMENT (To Prospectus dated January 31, 2024) 7,400,000 Units (Each Unit consisting of One Common Share and One Common Warrant to purchase One Common Share) 7,400,000 Common Shares Underlying Common Warrants BriaCell Therapeutics Corp. BriaCell Therapeutics Corp. (the “Company” or “BriaCell”) is offering an aggregate of 7, |
|
| December 11, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-276650 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securit |
|
| December 10, 2024 |
BCTX / BriaCell Therapeutics Corp. / L5 Capital Inc. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* BriaCell Therapeutics Corp. (Name of Issuer) COMMON SHARES, NO PAR VALUE (Title of Class of Securities) 10778Y302 (CUSIP Numbe |
|
| December 5, 2024 |
BCTX / BriaCell Therapeutics Corp. / L5 Capital Inc. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* BriaCell Therapeutics Corp. (Name of Issuer) COMMON SHARES, NO PAR VALUE (Title of Class of Securities) 10778Y302 (CUSIP Numbe |
|
| November 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 23, 2024 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organ |
|
| November 14, 2024 |
BCTX / BriaCell Therapeutics Corp. / CVI Investments, Inc. - SC 13G/A Passive Investment SC 13G/A 1 tm2428264d2sc13ga.htm SC 13G/A CUSIP No: 107930109 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* BriaCell Therapeutics Corp. (Name of Issuer) Common Shares, no par value ( |
|
| November 1, 2024 |
Exhibit 99.2 BRIAPRO THERAPEUTICS CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS For the Year Ended July 31, 2024 (Expressed in U.S. Dollars) The following Management’s Discussion and Analysis (“MD&A”) for BRIAPRO THERAPEUTICS CORP. (“BriaPro” or the “Company”) is prepared as of November 1, 2024 and relates to the financial condition and results of operations of the Company for the year ended July 31, |
|
| November 1, 2024 |
Exhibit 99.1 BRIAPRO THERAPEUTIC CORP. CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED JULY 31, 2024 (Expressed in United States Dollars) Independent Auditor’s Report To the Shareholders of BriaPro Therapeutics Corp.: Opinion We have audited the consolidated financial statements of BriaPro Therapeutics Corp. (the “Company”), which comprise the consolidated statements of financial position a |
|
| November 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 1, 2024 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organi |
|
| October 29, 2024 |
Exhibit 21.1 List of Subsidiaries 1. BriaCell Therapeutics Corp., a Delaware corporation 2. Sapientia Pharmaceuticals Inc., a Delaware corporation 3. BriaPro Therapeutics Corp., a British Columbia corporation |
|
| October 29, 2024 |
Exhibit 97.1 BRIACELL THERAPEUTICS, CORP. CLAWBACK POLICY EFFECTIVE DECEMBER 1, 2023 1. Purpose. The purpose of this Briacell Therapeutics, Corp. (the “Company”) Clawback Policy (this “Policy”) is to enable the Company to recover Erroneously Awarded Compensation from Covered Executive Officers in the event that the Company is required to prepare an Accounting Restatement. This Policy is designed t |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from [●] to [●] Commission File Number: 001-40101 BRIACELL THER |
|
| October 2, 2024 |
Exhibit 10.1 PLACEMENT AGENCY AGREEMENT between BRIACELL THERAPEUTICS CORP. and THINKEQUITY LLC BRIACELL THERAPEUTICS CORP. PLACEMENT AGENCY AGREEMENT New York, New York October 1, 2024 ThinkEquity LLC 17 State Street, 41st Fl New York, NY 10004 Ladies and Gentlemen: This Placement Agency Agreement (the “Agreement”) sets forth the terms upon which ThinkEquity LLC (“ThinkEquity” or the “Placement A |
|
| October 2, 2024 |
ThinkEquity The date of this prospectus supplement is October 1, 2024 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-276650 PROSPECTUS SUPPLEMENT (To Prospectus dated January 31, 2024) 5,128,500 Units (Each Unit consisting of One Common Share and One Common Warrant to purchase One Common Share) 5,128,500 Common Shares Underlying Common Warrants 256,425 Placement Agent Warrants to Purchase Common Shares 256,425 Common Shares Underlying the Placement Agent Warr |
|
| October 2, 2024 |
BriaCell Therapeutics Announces $5 Million Offering Exhibit 99.1 BriaCell Therapeutics Announces $5 Million Offering Priced At-the-Market Under Nasdaq Rules PHILADELPHIA and VANCOUVER, British Columbia, Oct. 01, 2024 (GLOBE NEWSWIRE) - BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pri |
|
| October 2, 2024 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 1, 2024 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organiz |
|
| October 2, 2024 |
Form of Placement Agent Warrant Exhibit 4.2 Placement Agent’s Warrant Agreement WARRANT TO PURCHASE COMMON SHARES BRIACELL THERAPEUTICS CORP. Warrant Shares: Initial Exercise Date: October 2, 2024 THIS WARRANT TO PURCHASE COMMON SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, a |
|
| October 2, 2024 |
Exhibit 4.1 FORM OF WARRANT TO PURCHASE COMMON SHARES BRIACELL THERAPEUTICS CORP. Warrant Shares: Initial Exercise Date: October 2, 2024 THIS WARRANT TO PURCHASE COMMON SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after Octob |
|
| October 2, 2024 |
BriaCell Therapeutics Announces Closing of $5 Million Offering Exhibit 99.2 BriaCell Therapeutics Announces Closing of $5 Million Offering Philadelphia & Vancouver, British Columbia – October 2, 2024 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 1, 2024 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organiz |
|
| October 1, 2024 |
Exhibit 99.1 BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with “Eye-Bulging” Tumor ● Dramatic anti-tumor response includes complete resolution of right temporal lobe brain metastasis in patient with “Eye-Bulging” metastatic breast cancer ● Heavily pre-treated patient had failed 8 prior regimens including antibody-drug conjugate (ADC) therapy and continues to receiv |
|
| September 16, 2024 |
BCTX / BriaCell Therapeutics Corp. / CVI Investments, Inc. - SC 13G Passive Investment CUSIP No: 107930109 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* BriaCell Therapeutics Corp. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 107930109 ( |
|
| September 16, 2024 |
CUSIP No: 107930109 Exhibit I LIMITED POWER OF ATTORNEY THIS LIMITED POWER OF ATTORNEY given on the 16th day of July, 2015 by CVI Investments, Inc. |
|
| September 16, 2024 |
CUSIP No: 107930109 EXHIBIT II JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the common shares of BriaCell Therapeutics Corp. |
|
| September 12, 2024 |
BriaCell Therapeutics Announces $8.5 Million Offering Exhibit 99.1 BriaCell Therapeutics Announces $8.5 Million Offering Priced At-the-Market Under Nasdaq Rules PHILADELPHIA and VANCOUVER, British Columbia, Sept. 11, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the |
|
| September 12, 2024 |
Exhibit 4.1 Form of Placement Agent’s Warrant Agreement THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIG |
|
| September 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 11, 2024 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or orga |
|
| September 12, 2024 |
BriaCell Therapeutics Announces Closing of $8.5 Million Offering Exhibit 99.2 BriaCell Therapeutics Announces Closing of $8.5 Million Offering Philadelphia & Vancouver, British Columbia – September 12, 2024 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-ef |
|
| September 12, 2024 |
Exhibit 10.1 PLACEMENT AGENCY AGREEMENT between BRIACELL THERAPEUTICS CORP. and THINKEQUITY LLC BRIACELL THERAPEUTICS CORP. PLACEMENT AGENCY AGREEMENT New York, New York September 11, 2024 ThinkEquity LLC 17 State Street, 41st Fl New York, NY 10004 Ladies and Gentlemen: This Placement Agency Agreement (the “Agreement”) sets forth the terms upon which ThinkEquity LLC (“ThinkEquity” or the “Placemen |
|
| September 12, 2024 |
ThinkEquity The date of this prospectus supplement is September 11, 2024 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-276650 PROSPECTUS SUPPLEMENT (To Prospectus dated January 31, 2024) 12,325,000 Common Shares BriaCell Therapeutics Corp. BriaCell Therapeutics Corp. (the “Company” or “BriaCell”) is offering 12,325,000 common shares, no par value, of the Company (the “common shares”), at an offering price of $0.69 per share, pursuant to this prospectus suppleme |
|
| September 11, 2024 |
BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+™ for Prostate Cancer Exhibit 99.2 BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+™ for Prostate Cancer ● BriaCell has received positive feedback from its Pre-Investigational New Drug Application (Pre-IND) meeting with FDA for Bria-PROS+™ in prostate cancer ● The meeting provides a clear path towards filing an IND and conducting a Phase 1/2 study of Bria-PROS+™ PHILADELPHIA and VANCOUVER, British Co |
|
| September 11, 2024 |
Exhibit 99.1 BriaCell Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting PHILADELPHIA and VANCOUVER, British Columbia, Sept. 09, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces a |
|
| September 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 9, 2024 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organ |
|
| September 11, 2024 |
BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer Exhibit 99.3 BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer ● Median overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in combination with immune checkpoint inhibitor ● OS of 15.6 months compares favorably with 6.7-9.3 months reported for similar patients in the literature ● Ongoing Phase 3 study investigating Bria-IMT™ in similar metastatic b |
|
| August 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 22, 2024 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organiz |
|
| July 18, 2024 |
Exhibit 99.1 BriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast Cancer ● Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients in similar studies 1,2, 3 ● Significant reduction of “Eye-Bulging” metastatic breast cancer tumor was previously reported ● Heavily pre-treated patient had failed 8 p |
|
| July 18, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 18, 2024 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organizat |
|
| July 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 3, 2024 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organizati |
|
| June 14, 2024 |
Exhibit 99.2 BRIAPRO THERAPEUTICS CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS For the three and nine months ended April 30, 2024 (Expressed in U.S. Dollars) The following Management’s Discussion and Analysis (“MD&A”) for BRIAPRO THERAPEUTICS CORP. (“BriaPro” or the “Company”) is prepared as of June 14, 2024 and relates to the unaudited condensed interim financial condition and results of operations |
|
| June 14, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 14, 2024 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organizat |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40101 BRIACELL THERAPE |
|
| June 14, 2024 |
Exhibit 99.1 BRIAPRO THERAPEUTIC CORP. CONDESED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTH PERIOD ENDED APRIL 30, 2024 (Unaudited) (Expressed in United States Dollars) NOTICE OF NO AUDITOR REVIEW OF THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS In accordance with National Instrument 51-102 Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of these cond |
|
| May 24, 2024 |
BCTX / BriaCell Therapeutics Corp. / L5 Capital Inc. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* BriaCell Therapeutics Corp. (Name of Issuer) COMMON SHARES, NO PAR VALUE (Title of Class of Securities) 10778Y302 (CUSIP Numbe |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 14, 2024 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organizati |
|
| May 17, 2024 |
BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Exhibit 99.1 BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2024 (GLOBE NEWSWIRE) – BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced it has entered in |
|
| May 17, 2024 |
Exhibit 4.2 PRE-FUNDED COMMON SHARE PURCHASE WARRANT BriaCell Therapeutics Corp. Warrant Shares: Issue Date: May [●], 2024 THIS PRE-FUNDED COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date her |
|
| May 17, 2024 |
Form of Securities Purchase Agreement Exhibit 10.1 EXECUTION VERSION Securities Purchase Agreement This Securities Purchase Agreement (this “Agreement”) is dated as of May 14, 2024, between BriaCell Therapeutics Corp., a corporation existing under the Business Corporations Act of British Columbia (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and |
|
| May 17, 2024 |
Exhibit 10.2 EXECUTION VERSION A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, New York 10022 May 14, 2024 BriaCell Therapeutics Corp. Attention: Dr. William V. Williams Suite 300 – 235 15th Street West Vancouver, BC V7T 2XI Re: Placement Agency Agreement Dear Dr. Williams: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Allian |
|
| May 17, 2024 |
Exhibit 4.1 COMMON SHARE PURCHASE WARRANT BriaCell Therapeutics Corp. Warrant Shares: [●] Original Issuance Date: May 17, 2024 Initial Exercise Date: November 17, 2024 THIS COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at |
|
| May 17, 2024 |
Exhibit 4.3 PLACEMENT AGENT COMMON SHARE PURCHASE WARRANT BriaCell Therapeutics Corp. Warrant Shares: [●] Original Issuance Date: May 17, 2024 Initial Exercise Date: November 17, 2024 THIS PLACEMENT AGENT COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the cond |
|
| May 16, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-276650 PROSPECTUS SUPPLEMENT (to Prospectus dated January 22, 2024) 2,302,935 Common Shares Pre-Funded Warrants to purchase up to 100,000 Common Shares Common Warrants to purchase up to 2,402,935 Common Shares Up to 100,000 Common Shares Underlying the Pre-Funded Warrants Up to 2,402,935 Common Shares Underlying the Common Warrants Placement Ag |
|
| April 2, 2024 |
Exhibit 99.2 BRIAPRO THERAPEUTICS CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS For the three and six months ended January 31, 2024 (Expressed in U.S. Dollars) The following Management’s Discussion and Analysis (“MD&A”) for BRIAPRO THERAPEUTICS CORP. (“BriaPro” or the “Company”) is prepared as of April 1, 2024 and relates to the unaudited condensed interim financial condition and results of operation |
|
| April 2, 2024 |
Exhibit 99.1 BRIAPRO THERAPEUTIC CORP. CONDESED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTH PERIOD ENDED JANUARY 31, 2024 (Unaudited) (Expressed in United States Dollars) NOTICE OF NO AUDITOR REVIEW OF THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS In accordance with National Instrument 51-102 Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of these con |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 1, 2024 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organizat |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40101 BRIACELL THERA |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 30, 2024 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organi |
|
| January 29, 2024 |
January 29, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Attention: Alan Campbell Re: BriaCell Therapeutics Corp. Registration Statement on Form S-3 File No. 333-276650 Filed January 22, 2024 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (t |
|
| January 22, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) BRIACELL THERAPEUTICS CORP. |
|
| January 22, 2024 |
As filed with the Securities and Exchange Commission on January 22, 2024 Registration Statement No. |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| December 20, 2023 |
Exhibit 99.1 BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset ● In the subset of Antibody-Drug Conjugate (ADC) refractory patients, Overall Survival (OS) data of BriaCell’s combination regimen exceeded that of similar studies* ● Progression Free Survival (PFS) was similar or better than last regimen in 40% of the pa |
|
| December 20, 2023 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 20, 2023 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organ |
|
| December 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40101 BRIACELL THERA |
|
| December 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 14, 2023 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organ |
|
| December 14, 2023 |
Exhibit 99.2 BRIAPRO THERAPEUTICS CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS For the three months ended October 31, 2023 (Expressed in U.S. Dollars) The following Management’s Discussion and Analysis (“MD&A”) for BRIAPRO THERAPEUTICS CORP. (“BriaPro” or the “Company”) is prepared as of December 14, 2023 and relates to the unaudited condensed interim financial condition and results of operations of |
|
| December 14, 2023 |
Exhibit 99.1 BRIAPRO THERAPEUTIC CORP. CONDESED INTERIM FINANCIAL STATEMENTS FOR THE THREE MONTH PERIOD ENDED OCTOBER 31, 2023 (Unaudited) (Expressed in United States Dollars) F-1 BriaPro Therapeutics Corp. Unaudited Condensed Interim Statements of Financial Position As at October 31, 2023 (Expressed in US Dollars) October 31, 2023 July 31, 2023 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 1 |
|
| November 30, 2023 |
BriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic Tumor Exhibit 99.1 BriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic Tumor ● After only 3 cycles, patient experienced a remarkable improvement of eye-bulging “proptosis” caused by orbital metastatic breast cancer tumor behind the eye. ● Significant ocular pain reduction recorded. ● Heavily treated patient had 7 prior failed regimens. ● The patient continues to receiv |
|
| November 30, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 30, 2023 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organ |
|
| November 3, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 3, 2023 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organi |
|
| November 3, 2023 |
Exhibit 99.1 BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ IND ● BriaCell demonstrates unprecedented broad immune system activation in tumor models by BriaCell’s next generation breast and prostate cancer immunotherapies ● Data supports furt |
|
| October 25, 2023 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of August 31, 2023, BriaCell Therapeutics Corp. (“we,” “our,” “us” or the “Company”) had the following classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): (i) our common shares and (ii) our public w |
|
| October 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from [●] to [●] Commission File Number: 001-40101 BRIACELL THER |
|
| October 25, 2023 |
Exhibit 99.1 BRIAPRO THERAPEUTIC CORP. FINANCIAL STATEMENTS FOR THE PERIOD ENDED JULY 31, 2023 (Expressed in United States Dollars) F-1 F-2 F-3 BriaPro Therapeutics Corp. Statement of Financial Position As at July 31, 2023 (Expressed in US Dollars) July 31, 2023 ASSETS CURRENT ASSETS: Cash $ 1 Total current assets 1 Total assets $ 1 LIABILITIES AND SHAREHOLDERS’ EQUITY Total liabilities: $ - SHARE |
|
| October 25, 2023 |
Exhibit 99.2 BRIAPRO THERAPEUTICS CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS For the Year Ended July 31, 2023 (Expressed in U.S. Dollars) The following Management’s Discussion and Analysis (“MD&A”) for BRIAPRO THERAPEUTICS CORP. (“BriaPro” or the “Company”) is prepared as of October 25, 2023 and relates to the financial condition and results of operations of the Company for the year ended July 31, |
|
| October 25, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 25, 2023 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organi |
|
| September 8, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 8, 2023 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organ |
|
| September 8, 2023 |
Exhibit 99.1 BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer ● Median overall survival of 13.5 months in BriaCell’s advanced metastatic breast cancer patients (vs. 6.7-9.8 months for similar patients reported in the literature) ● 21 out of 29 patients treated since 2022 are still alive suggesting a strong survival benefit for BriaCell’s |
|
| September 7, 2023 |
Exhibit 3.1 |
|
| September 7, 2023 |
Exhibit 3.2 |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 31, 2023 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organiz |
|
| August 31, 2023 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 31, 2023 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organiz |
|
| August 31, 2023 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 31, 2023 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organiz |
|
| August 31, 2023 |
Exhibit 99.1 BRIACELL THERAPEUTICS CORP. ANNOUNCES CLOSING OF PLAN OF ARRANGEMENT SPINNING OUT BRIAPRO THERAPEUTICS CORP. TO EXISTING SHAREHOLDERS ● BriaCell Therapeutics Corp. closes Arrangement effecting the distribution described in the plan of arrangement. Toronto, Ontario, August 31, 2023 - BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical- |
|
| August 31, 2023 |
Exhibit 99.1 BRIACELL THERAPEUTICS CORP. ANNOUNCES CLOSING OF PLAN OF ARRANGEMENT SPINNING OUT BRIAPRO THERAPEUTICS CORP. TO EXISTING SHAREHOLDERS ● BriaCell Therapeutics Corp. closes Arrangement effecting the distribution described in the plan of arrangement. Toronto, Ontario, August 31, 2023 - BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical- |
|
| August 25, 2023 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 25, 2023 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organiz |
|
| August 25, 2023 |
Exhibit 99.1 BriaCell Receives Court Approval for the Share Arrangement Spinning Out BriaPro Therapeutics (SpinCo) to Existing Shareholders ● August 31, 2023 is the expected effective date for the distribution contemplated by the Arrangement. PHILADELPHIA and VANCOUVER, British Columbia, Aug. 25, 2023 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or th |
|
| August 21, 2023 |
Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 18, 2023 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organiz |
|
| August 21, 2023 |
BRIACELL THERAPEUTICS CORP. ANNOUNCES VOTING RESULTS FROM SPECIAL MEETING Exhibit 99.1 BRIACELL THERAPEUTICS CORP. ANNOUNCES VOTING RESULTS FROM SPECIAL MEETING ● Shareholders overwhelmingly approved the spinout of BriaPro Therapeutics (Spinco) which includes specific pipeline assets including Bria-TILsRx and and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer ● Share reorganization expected to take place immediately prior to the closi |
|
| July 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| June 27, 2023 |
FDA Approves BriaCell’s Pivotal Registrational Study Design in Advanced Metastatic Breast Cancer Exhibit 99.1 FDA Approves BriaCell’s Pivotal Registrational Study Design in Advanced Metastatic Breast Cancer PHILADELPHIA, PA and VANCOUVER, British Columbia, June 27, 2023— BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage immunotherapy company driven to fight cancer and improve patients’ lives, announces that it has received approval fr |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 27, 2023 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organizat |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40101 BRIACELL THERAPE |
|
| June 14, 2023 |
Master Service and Technology Agreement dated May 9, 2023* Exhibit 10.1 Master Service and Technology Agreement THIS AGREEMENT is effective as of May 9, 2023 (this “Agreement”). Parties (1) Prevail InfoWorks, Inc. is a corporation having its principal place of business at 211 North 13th Street, Suite 600, Philadelphia, PA 19107-1610, USA (“Prevail”); and (2) BriaCell Therapeutics Corp. is a corporation having its principal place of business at 2929 Arch S |
|
| May 31, 2023 |
Exhibit 10.1 ARRANGEMENT AGREEMENT THIS ARRANGEMENT AGREEMENT is dated as of the 24th day of May, 2023. BETWEEN: BRIACELL THERAPEUTICS CORP., a corporation existing under the Business Corporations Act (British Columbia) (“BriaCell”) - and - BRIAPRO THERAPEUTICS CORP., a corporation existing under the Business Corporations Act (British Columbia) (“SpinCo”, and together with BriaCell, the “Parties” |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 24, 2023 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organizati |
|
| May 31, 2023 |
BriaCell Enters Definitive Arrangement Agreement for the Spin Out of BriaPro Therapeutics Corp. Exhibit 99.1 BriaCell Enters Definitive Arrangement Agreement for the Spin Out of BriaPro Therapeutics Corp. ● Special Shareholder Meeting to be Held in July 2023 PHILADELPHIA and VANCOUVER, British Columbia, May 25, 2023 — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 19, 2023 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organizati |
|
| May 22, 2023 |
BriaCell Closes $4 Million Strategic Investment by Prevail Partners, LLC at US$8.63 per Share Exhibit 99.1 BriaCell Closes $4 Million Strategic Investment by Prevail Partners, LLC at US$8.63 per Share PHILADELPHIA and VANCOUVER, British Columbia, May 19, 2023— BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that the Company has compl |
|
| May 15, 2023 |
Exhibit 10.2 STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (“Agreement”) is made and entered into as of May 12, 2023 (“Effective Date”), between BriaCell Therapeutics Corp. (“Company” or the “Company”) and Prevail Partners, LLC (“Prevail Partners”), Tax ID# 27-0256095. Company and Prevail Partners are collectively referred to herein as the “Parties.” WITNESSETH WHEREAS, Company identifies |
|
| May 15, 2023 |
Exhibit 10.1 Master Service and Technology Agreement THIS AGREEMENT is effective as of May 9, 2023 (this “Agreement”). Parties (1) Prevail InfoWorks, Inc. is a corporation having its principal place of business at 211 North 13th Street, Suite 600, Philadelphia, PA 19107-1610, USA (“Prevail”); and (2) BriaCell Therapeutics Corp. is a corporation having its principal place of business at 2929 Arch S |
|
| May 15, 2023 |
Exhibit 99.1 BriaCell Announces $4 Million Strategic Investment and Clinical Alliance with Prevail Partners, LLC and Prevail InfoWorks, Inc. ● Prevail Partners, LLC to purchase 463,408 BriaCell common shares at a price of $8.63 for gross proceeds of $4 million, representing a 20% premium to the trailing thirty (30) trading day VWAP. ● Prevail InfoWorks, Inc. to act as Contract Research Organizatio |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2023 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organizatio |
|
| April 17, 2023 |
Exhibit 99.5 |
|
| April 17, 2023 |
Exhibit 99.4 |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 17, 2023 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organiza |
|
| April 17, 2023 |
Exhibit 99.2 |
|
| April 17, 2023 |
Exhibit 99.1 BriaCell Presents Positive Data Demonstrating Survival and Clinical Benefits in Advanced Metastatic Breast Cancer at the 2023 AACR ● 15 of 18 patients remain alive of those recruited since the study reopened in 2021. ● Longer than expected patient survival data highlights tolerability and clinical effectiveness of BriaCell’s combination treatment. ● The Bria-IMT™ combination regimen a |
|
| April 17, 2023 |
Exhibit 99.3 |
|
| March 30, 2023 |
Exhibit 99.1 BriaCell Announces Intention to Spin-Out Certain Pre-Clinical Assets into a Newly Created “SpinCo” Entity whereby Shareholders to Receive One New Share of “SpinCo” in Addition to Each Current Share of BriaCell Already Held ● SpinCo Assets (SpinCo) includes Bria-TILsRx™, and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer. ● SpinCo’s goal is to potent |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 30, 2023 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organiza |
|
| March 20, 2023 |
As filed with the Securities and Exchange Commission on March 20, 2023 As filed with the Securities and Exchange Commission on March 20, 2023 Registration No. |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40101 BRIACELL THERA |
|
| March 13, 2023 |
March 13, 2023 United States Securities and Exchange Commission Washington, D.C. 20549 Division of Corporation Finance Attention: Christine Torney and Vanessa Robertson Re: BriaCell Therapeutics Corp. Form 10-K for the Fiscal Year Ended July 31, 2022 Filed October 28, 2022 File No. 001-40101 Ladies and Gentlemen: On behalf of BriaCell Therapeutics Corp. (the “Company”), please find below our respo |
|
| February 23, 2023 |
BriaCell Reports Positive Survival Data in Advanced Metastatic Breast Cancer Exhibit 99.1 BriaCell Reports Positive Survival Data in Advanced Metastatic Breast Cancer ● 9 of 11 women remain alive from 2021/2022 dosing, highlighting strong survival benefits. ● Remains well tolerated with no dose limiting toxicities. ● Primary endpoint in pending pivotal trial will be survival, as agreed by the FDA. ● 9 additional patients have been screened/enrolled in the study, incrementa |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 23, 2023 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organ |
|
| February 15, 2023 |
Exhibit 3.1 INFORMATION REGARDING ALTERATION TO ARTICLES 1. The attached is a copy of an alteration made to the Articles of: Briacell Therapeutics Corp. 2. The alteration was: (a) Passed by the type of resolution and on the date indicated below: Director(s) resolution dated: Ordinary resolution dated: February 9, 2023 deleting and replacing Article 11.3 in its entirety to the form attached hereto |
|
| February 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 9, 2023 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organi |
|
| February 14, 2023 |
BCTX / BriaCell Therapeutics Corp. / Lynwood Capital Management Inc. - SC 13G/A Passive Investment SC 13G/A 1 tm236410d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* BriaCell Therapeutics Corp. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 10778Y302 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the a |
|
| February 10, 2023 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 9, 2023 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organi |
|
| February 10, 2023 |
BRIACELL THERAPEUTICS CORP. ANNOUNCES RESULTS OF SHAREHOLDER MEETING Exhibit 99.1 BRIACELL THERAPEUTICS CORP. ANNOUNCES RESULTS OF SHAREHOLDER MEETING PHILADELPHIA, PA and VANCOUVER, British Columbia, February 9, 2023 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce the results of its annual general and speci |
|
| January 24, 2023 |
BriaCell CEO Letter to Shareholders Exhibit 99.1 BriaCell CEO Letter to Shareholders ● Positive FDA feedback on our pivotal study for lead clinical candidate Bria-IMT™ in combination with a checkpoint inhibitor could greatly accelerate the path to commercialization. ● Successful completion of the pivotal study could be followed by a Biologics License Application submission and commercialization. ● Pivotal study’s primary endpoint to |
|
| January 24, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 24, 2023 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organi |
|
| January 23, 2023 |
BriaCell to Investigate Alleged Illegal Trading of Public Securities Exhibit 99.1 BriaCell to Investigate Alleged Illegal Trading of Public Securities PHILADELPHIA, PA and VANCOUVER, British Columbia, January 23, 2023— BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announced today that it has approved measures to address alleged i |
|
| January 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 23, 2023 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organi |
|
| January 18, 2023 |
Exhibit 99.1 BriaCell Announces Positive End of Phase II Meeting with the FDA for Bria-IMT™ Combination in Advanced Metastatic Breast Cancer ● BriaCell has received agreement and positive feedback from its End of Phase II meeting with the FDA for lead clinical candidate, Bria-IMT™ in combination with a checkpoint inhibitor, in advanced metastatic breast cancer. ● After reviewing BriaCell’s Fast Tr |
|
| January 18, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 18, 2023 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organi |
|
| January 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Information Required in Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☒ Definitive Information Statement BRIACELL THERAPEUTICS CORP. (Name of Company As Specified In Charter) Not Applicable (Name of Person(s) Filing t |
|
| January 10, 2023 |
Exhibit 99.1 BriaCell Announces New Patent Issuance, Bria-OTS™ IND Timing Guidance, and Additional Clinical Sites to Boost Enrolment ● BriaCell’s new patent protects its novel personalized off-the-shelf cell-based technology for breast cancer and multiple other cancer indications until 2040. ● BriaCell expects to initiate its Bria-OTS™ clinical study under an Investigational New Drug Application ( |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2023 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organi |
|
| January 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Information Required in Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Definitive Information Statement BRIACELL THERAPEUTICS CORP. (Name of Company As Specified In Charter) Not Applicable (Name of Person(s) Filing t |
|
| December 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40101 BRIACELL THERA |
|
| December 8, 2022 |
Exhibit 99.3 |
|
| December 8, 2022 |
Exhibit 99.2 |
|
| December 8, 2022 |
Exhibit 99.1 BriaCell Announces Positive Clinical and Quality of Life Data in Advanced Metastatic Breast Cancer at 2022 San Antonio Breast Cancer Symposium® ● Positive clinical data reported includes tumor shrinkage, disease control, progression free survival, and potential long term survival benefit in advanced metastatic breast cancer patients treated with the Bria-IMT™ combination regimen. ● “B |
|
| December 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 8, 2022 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organi |
|
| December 8, 2022 |
Exhibit 99.4 |
|
| November 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 30, 2022 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organ |
|
| November 30, 2022 |
Exhibit 99.1 IPA’s Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies VICTORIA, VANCOUVER, BRITISH COLUMBIA (CANADA), and PHILADELPHIA, PA, November 30, 2022 – IPA (IMMUNOPRECISE ANTIBODIES LTD.) ( “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that |
|
| November 10, 2022 |
Exhibit 99.1 BriaCell Reports Positive Breast Cancer Efficacy Data with Bria-IMT? Immunotherapy Treatment at SITC Annual Meeting ? Bria-IMT? regimen in combination with Incyte?s retifanlimab produced evidence of disease control, tumor shrinkage, and potential survival benefit amongst BriaCell?s recent 12 patient cohort in advanced breast cancer. ? The regimen remains well tolerated as recently rep |
|
| November 10, 2022 |
Exhibit 99.2 |
|
| November 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 10, 2022 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 47-1099599 (State or other jurisdiction of incorporation or organ |
|
| October 28, 2022 |
Exhibit 99.1 BriaCell Therapeutics Corp CONDENSED CONSOLIDATED FINANCIAL STATEMENTS As of October 31, 2021 Expressed in United States Dollars (Unaudited) NOTICE TO READER As of July 31, 2022, BriaCell Therapeutics Corp. (the ?Company?) determined that it no longer qualified as a ?foreign private issuer? as such term is defined in Rule 405 under the Securities Act. This means that, as of August 1, |
|
| October 28, 2022 |
Exhibit 99.4 Management?s Discussion and Analysis For the Three and Six Month Period Ended January 31, 2022 (in US Dollars) NOTICE TO READER As of July 31, 2022, BriaCell Therapeutics Corp. (the ?Company?) determined that it no longer qualified as a ?foreign private issuer? as such term is defined in Rule 405 under the Securities Act. This means that, as of August 1, 2022, the Company has been req |
|
| October 28, 2022 |
Exhibit 10.22 August 31, 2021 Dr. William V. Williams Chief Executive Officer BriaCell Therapeutics Corporation 180 Varick Street, 6th Floor New York, NY 10014 RE: New Compensation Package ? Retroact to July 1, 2021 Dear Bill, With appreciation and recognition of your important contributions and dedicated service to the Company, its future patients and shareholders, I am pleased to present you wit |
